Research programme: antisense oligonucleotide therapeutics - Praxis Precision Medicines
Latest Information Update: 02 Mar 2022
At a glance
- Originator Praxis Precision Medicines
- Class Antiepileptic drugs; Antisense oligonucleotides; Behavioural disorder therapies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autistic disorder; Epilepsy
Most Recent Events
- 31 Dec 2021 Praxis Precision Medicine and Cerebral Therapeutics signs research collaboration for antisense oligonucleotides in December 2021
- 17 Mar 2021 Praxis Precision Medicines enters into a research collaboration with The Florey Institute of Neuroscience and Mental Health to develop antisense oligonucleotides
- 17 Mar 2021 Early research in Autistic disorder in USA (unspecified route)